Bionomics (ASX:BNO) has announced the pricing of an underwritten follow-on offering in the US of 641,026 American Depositary Shares (ADS), each representing 180 ordinary shares of the company, at a public offering price of US$7.80 per ADS.
Bionomics is developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need.
The offering price of US$7.80 per ADS (A$0.0641 per ordinary share) represents a 1.63 per cent discount to the volume-weighted average price for the 15 days on which trades of the company’s shares were recorded on ASX ending on 16 November 2022.
Bionomics has granted the underwriters an option to purchase up to an additional 96,153ADSs within 30 days from the closing date of the offering at the public offering price, less underwriting discounts and commissions.
The company said gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately US$5 million, assuming the underwriters do not exercise their option to purchase additional ADSs, or approximately US$5.7 million if the underwriters exercise their option to purchase additional ADSs in full.